【Adimmune Corp.】February 2026 Revenue NT$0.06 Billion (YoY -19.7%)
NQ Score
48/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Adimmune Corporation (4142), a vaccine and biopharmaceutical developer and manufacturer, announced its February 2026 revenue. The company's monthly revenue was NT$0.06 billion, a 19.7% decrease compared to the same period last year. This figure reflects seasonal factors, as the peak flu vaccine shipping season has passed, leading to a traditional off-peak season for revenue.
AI analysis data is not yet available.